Aethlon Medical Inc. has signed an important agreement to merge with North Immunology.

Sep 17, 2026, 8:11 AM ETDealRead the original at sec.gov

Bad for AEMD

Aethlon Medical agreed to merge with North Immunology and pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company, a large dilution and change of control for current holders.

AEMD · Aethlon Medical Inc.

AI read · Bad for AEMD

The AI's read

Aethlon is giving control to North Immunology and will leave its current holders with a small stake. The merger formula values North Immunology at $150,000,000 versus Aethlon at $16,500,000, producing heavy dilution. While the deal may bring a larger operating business and a Nasdaq listing, the facts show current Aethlon holders will be materially reduced in ownership and control.

Get alerts for AEMD

Follow Aethlon Medical Inc. (AEMD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AEMD

Free on the App Store and Google Play, or on the web.